The primary objective of this Crohn’s Disease (CD) Clinical Study is to study the efficacy and safety of Tulisokibart (MK-7240) in participants with moderately to severely active CD.
People may qualify to take part in this study if they are 18-75 years old and:
-
Have had CD for at least 3 months and currently have moderate-to-severe active CD
-
Demonstrated inadequate response, loss of response, or intolerance to one or more of the following categories of drugs: oral locally acting steroids, systemic steroids, immunomodulators, biologic and/or small molecule advanced therapies.
-
Do not have ulcerative colitis or indeterminate colitis
If you are eligible for this clinical study, you:
-
Will receive the study medicine or placebo (a placebo may look like the study medicine, but has no active ingredients) and study-related medical exams at no cost. You do not need to have health insurance to participate.
-
May be paid back for travel-related study costs, such as bus fare or gas for driving to and from the study site.
Please note, if the trial drug works and your Crohn’s disease gets better, you may receive a health benefit (this means it may help you).
If the trial drug does not work, or if you get the placebo, you may not receive a health benefit.
Ask your doctor if you may be eligible for this study.
For more information, visit https://classic.clinicaltrials.gov/ct2/show/NCT06430801.
Investigators: Merck & Co., Inc.
Project date:
September, 2024